WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60


Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
            Best Paper Award :
Dr. Muhammad Baqir MR Fakhrildin
Download Article: Click Here


Track Your Article



Pramod Singh Khatri* and Anupriya Singh


CLL is a lymphoid malignancy described by the amassing and proliferation of nonfunctional and monoclonal small CD5/CD19/CD- 20/CD23-positive lymphocytes in the blood, bone marrow, and lymphoid tissues. It is the most well-known adult leukemia in the India, with 20,000 new cases and approx. 5000 deaths in 2014. CLL is fundamentally a malady of old age with the middle age at finding being 70 years; its frequency in the male populace is accounted to be twice that of the female populace. Finding of CLL requires the vicinity of no less than 5,000 monoclonal mature B-lymphocytes per microliter in the peripheral blood. The treatment methodologies of CLL are exceedingly individualized with patients in the early and stable phases of CLL not requiring treatment. Be that as it may, those with clinically advanced disease will require treatment. Cytotoxic medications, for example, the alkylating agents (chlorambucil, cyclophosphamide, and Bendamustine), have been the pillar of chemotherapeutic treatment in CLL. In any case, their absence of specificity for CLL cells and toxicity to normal cells, especially hematopoietic and immune cells, have restricted their efficacy. Other treatment strategies incorporate purine nucleoside analogs (PNA, for example, Fludarabine and immunotherapeutic agents, for example, anti CD20 monoclonal antibodies (Rituximab, Ofatumumab and Alemtuzumab). A few regimens utilizing the mix of immunotherapy with chemotherapeutics medications are additionally as of now being utilized as a part of the treatment of CLL. A treatment regimen combining Fludarabine, cyclophosphamide, and Rituximab (FCR) is right now the gold standard treatment for CLL and has likewise demonstrated reaction in relapsed/obstinate cases.

Keywords: Rituximab, Ofatumumab, Alemtuzumab, Fludarabine, cyclophosphamide, and Rituximab (FCR).

[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More